Skip to main content

2021 | Tranquilizer | OriginalPaper | Buchkapitel

4. Anxiolytika

verfasst von : Prof. Dr. med. Ion-George Anghelescu, Otto Benkert

Erschienen in: Kompendium der Psychiatrischen Pharmakotherapie

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Anxiolytika im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Außerdem werden Substanzen besprochen, deren primäre Indikation außerhalb der Angststörungen liegt, die aber auch bei diesen wirksam sind.
Literatur
Zurück zum Zitat Baandrup L, Ebdrup BH, Rasmussen JØ et al (2018) Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 3:CD011481CrossRefPubMedPubMedCentral Baandrup L, Ebdrup BH, Rasmussen JØ et al (2018) Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 3:CD011481CrossRefPubMedPubMedCentral
Zurück zum Zitat Bandelow B, Sagebiel A, Belz M et al (2018) Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Brit J Psychiatry 212:333–338CrossRef Bandelow B, Sagebiel A, Belz M et al (2018) Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Brit J Psychiatry 212:333–338CrossRef
Zurück zum Zitat Bedse G, Bluett RJ, Patrick TA et al (2018) Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors. Transl Psychiatry 8(1):92CrossRef Bedse G, Bluett RJ, Patrick TA et al (2018) Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors. Transl Psychiatry 8(1):92CrossRef
Zurück zum Zitat Bonnet U, Scherbaum N (2017) How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 27:1185–1215CrossRef Bonnet U, Scherbaum N (2017) How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 27:1185–1215CrossRef
Zurück zum Zitat Buoli M, Grassi S, Serati M et al (2017) Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother 18(13):1373–1379CrossRef Buoli M, Grassi S, Serati M et al (2017) Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother 18(13):1373–1379CrossRef
Zurück zum Zitat Buth S, Holzbach R, Martens MS et al (2019) Problematic medication with benzodiazepines, „Z-drugs“, and opioid analgesics – an analysis of national health insurance prescription data from 2006–2016. Dtsch Arztebl Int 116:607–614PubMedPubMedCentral Buth S, Holzbach R, Martens MS et al (2019) Problematic medication with benzodiazepines, „Z-drugs“, and opioid analgesics – an analysis of national health insurance prescription data from 2006–2016. Dtsch Arztebl Int 116:607–614PubMedPubMedCentral
Zurück zum Zitat Caniff K, Telega E, Bostwick JR, Gardner KN (2018) Pregabalin as adjunctive therapy in benzodiazepine discontinuation. Am J Health Syst Pharm 75:67–71CrossRef Caniff K, Telega E, Bostwick JR, Gardner KN (2018) Pregabalin as adjunctive therapy in benzodiazepine discontinuation. Am J Health Syst Pharm 75:67–71CrossRef
Zurück zum Zitat Chen TY, Winkelman JW, Mao WC et al (2018) The use of benzodiazepine receptor agonists and the risk of hospitalization for pneumonia: a nationwide population-based nested case-control study. Chest 153(1):161–171CrossRef Chen TY, Winkelman JW, Mao WC et al (2018) The use of benzodiazepine receptor agonists and the risk of hospitalization for pneumonia: a nationwide population-based nested case-control study. Chest 153(1):161–171CrossRef
Zurück zum Zitat Fluyau D, Revadigar N, Manobianco BE (2018) Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol 8(5):147–168CrossRef Fluyau D, Revadigar N, Manobianco BE (2018) Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol 8(5):147–168CrossRef
Zurück zum Zitat Fond G, Berna F, Boyer L et al (2018) Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci 268(1):17–26CrossRef Fond G, Berna F, Boyer L et al (2018) Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci 268(1):17–26CrossRef
Zurück zum Zitat Gahr M, Hiemke C, Connemann BJ (2017) Update Opipramol. Fortschr Neurol Psychiatr 85:139–145CrossRef Gahr M, Hiemke C, Connemann BJ (2017) Update Opipramol. Fortschr Neurol Psychiatr 85:139–145CrossRef
Zurück zum Zitat Gottschalk MG, Domschke K (2018) Oxytocin and anxiety disorders. Curr Top Behav Neurosci 35:467–498CrossRef Gottschalk MG, Domschke K (2018) Oxytocin and anxiety disorders. Curr Top Behav Neurosci 35:467–498CrossRef
Zurück zum Zitat Hata T, Kanazawa T, Hamada T et al (2018) What can predict and prevent the long-term use of benzodiazepines? J Psychiatr Res 97:94–100CrossRef Hata T, Kanazawa T, Hamada T et al (2018) What can predict and prevent the long-term use of benzodiazepines? J Psychiatr Res 97:94–100CrossRef
Zurück zum Zitat Klass A, Glaubitz B, Tegenthoff M et al (2017) D-Cycloserine facilitates extinction learning and enhances extinction-related brain activation. Neurobiol Learn Memory 144:235–247CrossRef Klass A, Glaubitz B, Tegenthoff M et al (2017) D-Cycloserine facilitates extinction learning and enhances extinction-related brain activation. Neurobiol Learn Memory 144:235–247CrossRef
Zurück zum Zitat Lüddens H (2012) Anxiolytika und Hypnotika. In: Gründer G, Benkert O (Hrsg) Handbuch der Psychopharmakotherapie, 2. Aufl. Springer, Berlin Heidelberg New York, S 695–712CrossRef Lüddens H (2012) Anxiolytika und Hypnotika. In: Gründer G, Benkert O (Hrsg) Handbuch der Psychopharmakotherapie, 2. Aufl. Springer, Berlin Heidelberg New York, S 695–712CrossRef
Zurück zum Zitat Mataix-Cols D, Fernández de la Cruz L, Monzani B et al (2017) D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiatry 74(5):501–510CrossRef Mataix-Cols D, Fernández de la Cruz L, Monzani B et al (2017) D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiatry 74(5):501–510CrossRef
Zurück zum Zitat Molero Y, Larsson H, D’Onofrio BM et al (2019) Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ 365:l2147CrossRef Molero Y, Larsson H, D’Onofrio BM et al (2019) Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ 365:l2147CrossRef
Zurück zum Zitat Murphy CP, Singewald N (2019) Role of microRNAs in anxiety and anxiety-related disorders. Curr Top Behav Neurosci 42:185–219PubMed Murphy CP, Singewald N (2019) Role of microRNAs in anxiety and anxiety-related disorders. Curr Top Behav Neurosci 42:185–219PubMed
Zurück zum Zitat Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A (2017) The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiatry Rep 19:103CrossRef Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A (2017) The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiatry Rep 19:103CrossRef
Zurück zum Zitat Sanchez-Vidana DI, Po KK, Fung TK et al (2019) Lavender essential oil ameliorates depression-like behavior and increases neurogenesis and dendritic complexity in rats. Neurosci Lett 701:182–190CrossRef Sanchez-Vidana DI, Po KK, Fung TK et al (2019) Lavender essential oil ameliorates depression-like behavior and increases neurogenesis and dendritic complexity in rats. Neurosci Lett 701:182–190CrossRef
Zurück zum Zitat Schjerning O, Damkier P, Lykkegaard SE et al (2017) Pregabalin for anxiety in patients with schizophrenia – a randomized, double-blind placebo-controlled study. Schizophr Res 195:260–266CrossRef Schjerning O, Damkier P, Lykkegaard SE et al (2017) Pregabalin for anxiety in patients with schizophrenia – a randomized, double-blind placebo-controlled study. Schizophr Res 195:260–266CrossRef
Zurück zum Zitat Slee A, Nazareth I, Bondaronek P, Liu Y et al (2019) Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 393(10173):768–777CrossRef Slee A, Nazareth I, Bondaronek P, Liu Y et al (2019) Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 393(10173):768–777CrossRef
Zurück zum Zitat Soyka M (2017) Treatment of benzodiazepine dependence. N Eng J Med 376:1147–1157CrossRef Soyka M (2017) Treatment of benzodiazepine dependence. N Eng J Med 376:1147–1157CrossRef
Zurück zum Zitat Stubbs B, Vancampfort D, Rosenbaum S et al (2017) An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: a metaanalysis. Psychiatry Res 249:102–108CrossRef Stubbs B, Vancampfort D, Rosenbaum S et al (2017) An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: a metaanalysis. Psychiatry Res 249:102–108CrossRef
Zurück zum Zitat Wolter DK (2017) Benzodiazepine absetzen im Alter. Wann und, wenn ja, wie? Z Gerontol Geriatr 50:115–122CrossRef Wolter DK (2017) Benzodiazepine absetzen im Alter. Wann und, wenn ja, wie? Z Gerontol Geriatr 50:115–122CrossRef
Metadaten
Titel
Anxiolytika
verfasst von
Prof. Dr. med. Ion-George Anghelescu
Otto Benkert
Copyright-Jahr
2021
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-61753-3_4